Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (54 quarters reported)
$545M in Q1 2013 → $1.49B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| SR Scholar Rock Hldg Corp | 15.9% | Trimmed 52% | 4,311,092 | $237M |
| Krystal Biotech Inc | 15.8% | Trimmed 6.2% | 632,005 | $235M |
| Stoke Therapeutics Inc | 8.7% | Trimmed 5.2% | 3,945,920 | $129M |
| Immunome Inc | 7.0% | Trimmed 12% | 4,911,590 | $104M |
| Nurix Therapeutics Inc | 6.6% | Trimmed 47% | 4,073,787 | $98.8M |
| Absci Corporation | 5.2% | Trimmed 18% | 6,739,675 | $78.1M |
| Annexon Inc | 4.6% | Trimmed 18% | 11,869,877 | $67.8M |
| Regenxbio Inc | 3.5% | Unchanged | 4,368,804 | $52.3M |
| Shattuck Labs Inc | 3.2% | Added 24% | 6,892,033 | $47.8M |
| Neurogene Inc | 3.0% | Trimmed 3.2% | 1,412,199 | $44.4M |
| Beam Therapeutics Inc | 2.7% | Trimmed 5.9% | 1,164,259 | $40M |
| Agomab Therapeutics Nv | 2.4% | Added 1650% | 2,733,926 | $35.5M |
| Fate Therapeutics Inc | 2.3% | Unchanged | 12,872,946 | $34.8M |
| Ideaya Biosciences Inc | 1.6% | Added 23% | 640,202 | $23.9M |
| Silence Therapeutics PLC | 1.6% | Unchanged | 2,164,777 | $23.8M |
| Cogent Biosciences Inc | 1.3% | Trimmed 27% | 503,321 | $19.5M |
| Solid Biosciences Inc | 1.3% | Trimmed 3.1% | 1,948,695 | $19.5M |
| Nuvation Bio Inc | 1.2% | Trimmed 3.9% | 3,031,009 | $17.2M |
| CT Celldex Therapeutics Inc New | 1.1% | Added 66% | 433,921 | $16.1M |
| Climb Bio Inc | 1.1% | New | 1,226,330 | $16M |
| AO Alx Oncology Hldgs Inc | 1.0% | Trimmed 7.2% | 7,392,504 | $15.3M |
| Biomarin Pharmaceutical Inc | 1.0% | Added 53% | 265,169 | $15.2M |
| Xenon Pharmaceuticals Inc | 0.9% | Trimmed 13% | 229,374 | $13.8M |
| Zymeworks Inc | 0.9% | Unchanged | 491,654 | $12.9M |
| Adc Therapeutics Sa | 0.8% | Trimmed 25% | 11,526,710 | $12.3M |
| Aura Biosciences Inc | 0.8% | New | 1,666,667 | $11.8M |
| Odyssey Therapeutics Inc | 0.5% | New | 425,000 | $7.95M |
| Livanova PLC | 0.5% | Trimmed 14% | 93,154 | $7.66M |
| EL Establishment Labs Hldgs Inc | 0.5% | Trimmed 14% | 88,964 | $7.63M |
| Ceribell Inc | 0.5% | Unchanged | 386,786 | $7.52M |
| Dbv Technologies S A | 0.5% | Trimmed 16% | 410,440 | $6.73M |
| Insmed Inc | 0.4% | New | 51,234 | $5.46M |
| Prime Medicine Inc | 0.3% | Trimmed 13% | 1,389,632 | $5.13M |
| Atara Biotherapeutics Inc | 0.3% | Unchanged | 441,701 | $5.07M |
| Eupraxia Pharmaceuticals Inc | 0.3% | Trimmed 13% | 611,400 | $4.04M |
| Oric Pharmaceuticals Inc | 0.3% | Trimmed 13% | 362,010 | $3.92M |
| Ardelyx Inc | 0.2% | Trimmed 12% | 641,750 | $3.27M |
| Invivyd Inc | 0.2% | Trimmed 1.9% | 2,597,759 | $2.27M |
| Pliant Therapeutics Inc | 0.1% | Unchanged | 772,126 | $880K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SR Scholar Rock Hldg Corp | Trimmed | −4,755,529 | −$262M | 15.9% |
| Nurix Therapeutics Inc | Trimmed | −3,659,021 | −$88.8M | 6.6% |
| Agomab Therapeutics Nv | Added | +2,577,676 | +$33.5M | 2.4% |
| Absci Corporation | Trimmed | −1,513,641 | −$17.5M | 5.2% |
| Climb Bio Inc | New | +1,226,330 | +$16M | 1.1% |
| Krystal Biotech Inc | Trimmed | −41,500 | −$15.4M | 15.8% |
| Annexon Inc | Trimmed | −2,679,891 | −$15.3M | 4.6% |
| Immunome Inc | Trimmed | −647,295 | −$13.7M | 7.0% |
| Aura Biosciences Inc | New | +1,666,667 | +$11.8M | 0.8% |
| Shattuck Labs Inc | Added | +1,352,309 | +$9.39M | 3.2% |
Showing the 10 largest of 32 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SR Scholar Rock Hldg Corp | Added | +3,845,775 | +$189M | 29.5% |
| Rapt Therapeutics Inc | Exited | −885,927 | −$30M | — |
| Cogent Biosciences Inc | Trimmed | −749,882 | −$28.9M | 1.8% |
| Annexon Inc | Added | +4,499,124 | +$24.9M | 5.3% |
| Replimune Group Inc | Exited | −1,099,756 | −$10.7M | — |
| Biomarin Pharmaceutical Inc | New | +173,859 | +$9.82M | 0.7% |
| AO Alx Oncology Hldgs Inc | Added | +4,699,470 | +$9.42M | 1.1% |
| Xenon Pharmaceuticals Inc | Added | +128,792 | +$7.49M | 1.0% |
| Ideaya Biosciences Inc | Trimmed | −220,900 | −$7.36M | 1.1% |
| Nurix Therapeutics Inc | Trimmed | −361,100 | −$5.6M | 7.9% |
Showing the 10 largest of 31 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Zymeworks Inc | Trimmed | −3,214,096 | −$84.6M | 1.0% |
| Nurix Therapeutics Inc | Added | +4,415,514 | +$83.8M | 11.3% |
| SR Scholar Rock Hldg Corp | Added | +1,316,390 | +$58M | 16.9% |
| Livanova PLC | Trimmed | −808,745 | −$49.8M | 0.5% |
| Akero Therapeutics Inc | Exited | −747,818 | −$35.5M | — |
| Cogent Biosciences Inc | Trimmed | −771,200 | −$27.4M | 3.8% |
| 89bio Inc | Exited | −1,473,136 | −$21.7M | — |
| Annexon Inc | Added | +3,750,000 | +$18.8M | 3.7% |
| Immunome Inc | Added | +695,000 | +$14.9M | 9.0% |
| Rapt Therapeutics Inc | Added | +333,333 | +$11.3M | 2.2% |
Showing the 10 largest of 33 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Kymera Therapeutics Inc | Exited | −803,289 | −$35.1M | — |
| Replimune Group Inc | Trimmed | −4,128,973 | −$17.3M | 0.2% |
| Hinge Health Inc | Exited | −300,000 | −$15.5M | — |
| Prime Medicine Inc | Trimmed | −1,987,232 | −$11M | — |
| Cogent Biosciences Inc | Added | +761,078 | +$10.9M | 3.1% |
| Biohaven Ltd | Exited | −729,515 | −$10.3M | — |
| Boston Scientific Corp | Exited | −85,301 | −$9.16M | — |
| Ideaya Biosciences Inc | Added | +309,523 | +$8.42M | 2.0% |
| Verve Therapeutics Inc | Exited | −740,261 | −$8.31M | — |
| Zymeworks Inc | Trimmed | −444,877 | −$7.6M | 6.2% |
Showing the 10 largest of 33 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Amicus Therapeutics Inc | Trimmed | −8,344,671 | −$47.8M | 0.7% |
| SR Scholar Rock Hldg Corp | Trimmed | −469,242 | −$16.6M | 14.8% |
| Hinge Health Inc | New | +300,000 | +$15.5M | 1.7% |
| Cogent Biosciences Inc | Trimmed | −1,767,986 | −$12.7M | 1.1% |
| Boston Scientific Corp | Trimmed | −107,982 | −$11.6M | 1.0% |
| Krystal Biotech Inc | Trimmed | −74,204 | −$10.2M | 9.7% |
| Akero Therapeutics Inc | Trimmed | −164,966 | −$8.8M | 4.4% |
| EL Establishment Labs Hldgs Inc | Trimmed | −198,871 | −$8.49M | 0.6% |
| Immunovant Inc | Exited | −490,394 | −$8.38M | — |
| Zymeworks Inc | Trimmed | −638,318 | −$8.01M | 5.5% |
Showing the 10 largest of 43 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Amicus Therapeutics Inc | Added | +2,478,779 | +$20.2M | 7.4% |
| Boston Scientific Corp | Trimmed | −119,400 | −$12M | 1.8% |
| Akero Therapeutics Inc | Trimmed | −295,932 | −$12M | 3.6% |
| Stryker Corporation | Exited | −30,676 | −$11M | — |
| Intuitive Surgical Inc | Exited | −16,943 | −$8.84M | — |
| Ardelyx Inc | Exited | −1,576,259 | −$7.99M | — |
| IT Irhythm Technologies Inc | New | +56,844 | +$5.95M | 0.6% |
| Solid Biosciences Inc | Added | +1,403,925 | +$5.19M | 0.7% |
| SR Scholar Rock Hldg Corp | Trimmed | −151,600 | −$4.87M | 13.4% |
| Insulet Corp | Added | +17,550 | +$4.61M | 0.7% |
Showing the 10 largest of 50 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Augmedix Inc | Exited | −16,380,327 | −$38.5M | — |
| Catalent Inc | Exited | −595,570 | −$36.1M | — |
| SR Scholar Rock Hldg Corp | Trimmed | −688,956 | −$29.8M | 13.7% |
| Kymera Therapeutics Inc | Trimmed | −292,824 | −$11.8M | 3.1% |
| Ceribell Inc | New | +435,239 | +$11.3M | 0.8% |
| Amicus Therapeutics Inc | Trimmed | −1,191,702 | −$11.2M | 4.6% |
| Rapt Therapeutics Inc | Added | +5,970,785 | +$9.43M | 0.7% |
| Krystal Biotech Inc | Trimmed | −57,070 | −$8.94M | 8.2% |
| Neurogene Inc | Added | +355,416 | +$8.12M | 2.1% |
| Biontech Se | Trimmed | −70,985 | −$8.09M | 0.7% |
Showing the 10 largest of 56 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Krystal Biotech Inc | Trimmed | −210,833 | −$38.4M | 8.7% |
| Amicus Therapeutics Inc | Trimmed | −2,348,497 | −$25.1M | 5.2% |
| Biontech Se | New | +154,456 | +$18.3M | 1.1% |
| Blueprint Medicines Corp | Exited | −94,405 | −$10.2M | — |
| Oruka Therapeutics Inc | New | +411,728 | +$10.1M | 0.6% |
| Kymera Therapeutics Inc | Trimmed | −186,019 | −$8.8M | 3.9% |
| Replimune Group Inc | Trimmed | −780,913 | −$8.56M | 3.1% |
| Entrada Therapeutics Inc | Exited | −560,971 | −$7.99M | — |
| Akero Therapeutics Inc | Trimmed | −226,994 | −$6.51M | 2.3% |
| Intuitive Surgical Inc | Trimmed | −13,145 | −$6.46M | 0.8% |
Showing the 10 largest of 46 changes.
Loading...
